As of 2026-09-04 00:09 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
Prosecutors filed an indictment on 2024-12-03 charging Kim Seung-won with bribery for allegedly using an intermediary to influence a Food and Drug Safety official regarding a new drug approval. [1][7]
Kim Seung-won's inquiry team announced on 2026-04-03 that there is no evidence of him receiving political donations or gifts. [2] Seo Young-gyo, the Chairman of the National Assembly's Legislation and Justice Committee, stated on 2026-04-04 that the clinical trial bribery allegations against Kim Seung-won appear to be typical behavior among politicians. [3] Kim Seung-won responded to the intermediary's request on 2021-10-08 with the Korean word 'Oke' (Okay) and later instructed the intermediary to ask the Food and Drug Safety official to process the matter quickly. [4]
Photos released by the intermediary Yang in February 2022 show Kim Seung-won posing with Judge Jung, who denied the arrest warrant for the drug company founder, raising concerns about judicial bias. [5] Kim Seung-won was investigated in 2021 for soliciting expedited approval of a clinical trial for a Genentech COVID-19 treatment from then-Food and Drug Safety Institute Director Kim Kang-rim. [6][8]Los fiscales presentaron una acusación el 2024-12-03 imputando a Kim Seung-won por soborno, por presuntamente usar un intermediario para influir en un funcionario de Seguridad Alimentaria y Farmacéutica respecto a la aprobación de un nuevo medicamento. [1][7]
El equipo de investigación de Kim Seung-won anunció el 2026-04-03 que no hay evidencia de que haya recibido donaciones políticas o regalos. [2] Seo Young-gyo, presidente del Comité de Legislación y Justicia de la Asamblea Nacional, declaró el 2026-04-04 que las acusaciones de soborno en ensayos clínicos contra Kim Seung-won parecen ser un comportamiento típico entre los políticos. [3] Kim Seung-won respondió a la solicitud del intermediario el 2021-10-08 con la palabra coreana 'Oke' (Okay) y luego instruyó al intermediario para que pidiera al funcionario de Seguridad Alimentaria y Farmacéutica que procesara el asunto rápidamente. [4]
Fotos publicadas por el intermediario Yang en febrero de 2022 muestran a Kim Seung-won posando con el juez Jung, quien denegó la orden de arresto para el fundador de la compañía farmacéutica, lo que genera preocupaciones sobre parcialidad judicial. [5] Kim Seung-won fue investigado en 2021 por solicitar la aprobación acelerada de un ensayo clínico para un tratamiento contra la COVID-19 de Genentech al entonces director del Instituto de Seguridad Alimentaria y Farmacéutica, Kim Kang-rim. [6][8]
Proof8 sources · 2 publishers
What this stands on
Prosecutors filed an indictment on 2024-12-03 charging Kim Seung-won with bribery for allegedly using an intermediary to influence a Food and Drug Safety official regarding a new drug approval. · 동아일보
Kim Seung-won's inquiry team announced on 2026-04-03 that there is no evidence of him receiving political donations or gifts. · KyungHyangSinmun
Seo Young-gyo, the Chairman of the National Assembly's Legislation and Justice Committee, stated on 2026-04-04 that the clinical trial bribery allegations against Kim Seung-won appear to be typical behavior among politicians. · KyungHyangSinmun
Kim Seung-won responded to the intermediary's request on 2021-10-08 with the Korean word 'Oke' (Okay) and later instructed the intermediary to ask the Food and Drug Safety official to process the matter quickly. · 동아일보
Photos released by the intermediary Yang in February 2022 show Kim Seung-won posing with Judge Jung, who denied the arrest warrant for the drug company founder, raising concerns about judicial bias. · 동아일보
The Food and Drug Safety Institute approved the clinical trial on 2021-10-17, nine days after Kim Seung-won met with the intermediary at a restaurant in Yeouido, Seoul. · 동아일보
Kim Seung-won received a suspended prosecution ruling in December 2024 regarding the bribery allegations. · KyungHyangSinmun
Kim Seung-won was investigated in 2021 for soliciting expedited approval of a clinical trial for a Genentech COVID-19 treatment from then-Food and Drug Safety Institute Director Kim Kang-rim. · KyungHyangSinmun
1 of the 2 publishers publishes from South Korea. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Friday, September 4, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
1 of the 2 publishers publishes from South Korea. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.